This cohort study compares rates of 1-year adherence to glucagon-like peptide-1 receptor agonist or sodium-glucose cotransporter 2 inhibitor therapies by co-payment level among US adults with type 2 diabetes and/or heart failure. Here, SLC5A2 is linked to type 2 diabetes mellitus.